Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 10
Submit an article Journal homepage
408
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma

Ravi VijWashington University School of Medicine, St. Louis, MO, USACorrespondence[email protected]
,
Michael WangM. D. Anderson Cancer Center, Houston, TX, USA
,
Sundar JagannathMt Sinai Hospital, New York, NY, USA
,
Ruben NiesvizkyWeill Cornell Medical College, New York, NY, USA
,
Andrzej J. JakubowiakUniversity of Chicago Medical Center, Chicago, IL, USA
,
Edward KavalerchikOnyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA
,
Mei HuangOnyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA
&
David S. SiegelJohn Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA
 show all
Pages 2959-2961 | Received 08 Aug 2014, Accepted 14 Feb 2015, Published online: 12 May 2015

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Morie A. Gertz. (2015) Utility of the immunoglobulin free light chain assay for plasma cell disorders 2015. Leukemia & Lymphoma 56:10, pages 2757-2758.
Read now

Articles from other publishers (2)

Xiaoyu Yan, Xu Steven Xu, Katja C. Weisel, Maria‐Victoria Mateos, Pieter Sonneveld, Meletios A. Dimopoulos, Saad Zafar Usmani, Nizar J. Bahlis, Thomas Puchalski, Jon Ukropec, Kevin Bellew, Qi Ming, Steven Sun & Honghui Zhou. (2020) Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma. Clinical and Translational Science 13:6, pages 1345-1354.
Crossref
F Jonsson, Y Ou, L Claret, D Siegel, S Jagannath, R Vij, A Badros, S Aggarwal & R Bruno. (2015) A Tumor Growth Inhibition Model Based on M‐Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single‐Agent Carfilzomib Use. CPT: Pharmacometrics & Systems Pharmacology 4:12, pages 711-719.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.